As we progress further into 2019, we’d like to update you on the progress of our MGC Botanic division:
In 2018, our cannabis crop in the Czech Republic delivered 30% more flowers than the 2017 harvest and is being prepared for immediate transportation to its Slovenian extraction facility.
In addition, the Slovenian Ministry of Health has awarded us a permit for the extraction of phytocannabinoids for the creation of MXC’s own proprietary APIs (Active Pharmaceutical Ingredients).
We’re also pleased to report that we have successfully developed a new proprietary genetic strain, MXC-10, containing the highest level of THC (>35%) of any MXC strand launched to date.
The next step for our Botanic division is to begin the process of registering our four unique Cannabis Sativa strains (bred in the University of Slovenia Biotechnical faculty) in Europe for medical purposes — an enormous production and distribution milestone for MGC Pharma.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.